JPH11124372A5 - - Google Patents

Info

Publication number
JPH11124372A5
JPH11124372A5 JP1998224015A JP22401598A JPH11124372A5 JP H11124372 A5 JPH11124372 A5 JP H11124372A5 JP 1998224015 A JP1998224015 A JP 1998224015A JP 22401598 A JP22401598 A JP 22401598A JP H11124372 A5 JPH11124372 A5 JP H11124372A5
Authority
JP
Japan
Prior art keywords
isopropanol
filtrate
cooling
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998224015A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11124372A (ja
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed filed Critical
Publication of JPH11124372A publication Critical patent/JPH11124372A/ja
Publication of JPH11124372A5 publication Critical patent/JPH11124372A5/ja
Pending legal-status Critical Current

Links

JP10224015A 1997-08-08 1998-08-07 N−(4−トリフルオロメチルフェニル)−5−メチルイソオキサゾール−4−カルボキサミドの結晶形態 Pending JPH11124372A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE19734438:0 1997-12-17
DE19756093:8 1997-12-17
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009175137A Division JP2009280604A (ja) 1997-08-08 2009-07-28 N−(4−トリフルオロメチルフェニル)−5−メチルイソオキサゾール−4−カルボキサミドの結晶形態の製造方法

Publications (2)

Publication Number Publication Date
JPH11124372A JPH11124372A (ja) 1999-05-11
JPH11124372A5 true JPH11124372A5 (cg-RX-API-DMAC10.html) 2005-10-27

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10224015A Pending JPH11124372A (ja) 1997-08-08 1998-08-07 N−(4−トリフルオロメチルフェニル)−5−メチルイソオキサゾール−4−カルボキサミドの結晶形態
JP2009175137A Pending JP2009280604A (ja) 1997-08-08 2009-07-28 N−(4−トリフルオロメチルフェニル)−5−メチルイソオキサゾール−4−カルボキサミドの結晶形態の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009175137A Pending JP2009280604A (ja) 1997-08-08 2009-07-28 N−(4−トリフルオロメチルフェニル)−5−メチルイソオキサゾール−4−カルボキサミドの結晶形態の製造方法

Country Status (28)

Country Link
US (5) US6060494A (cg-RX-API-DMAC10.html)
EP (2) EP0903345B1 (cg-RX-API-DMAC10.html)
JP (2) JPH11124372A (cg-RX-API-DMAC10.html)
KR (2) KR100544041B1 (cg-RX-API-DMAC10.html)
CN (2) CN1181064C (cg-RX-API-DMAC10.html)
AR (1) AR015418A1 (cg-RX-API-DMAC10.html)
AT (2) ATE207065T1 (cg-RX-API-DMAC10.html)
AU (1) AU752764B2 (cg-RX-API-DMAC10.html)
BR (1) BR9806568A (cg-RX-API-DMAC10.html)
CA (1) CA2245267C (cg-RX-API-DMAC10.html)
CZ (3) CZ301426B6 (cg-RX-API-DMAC10.html)
DE (2) DE59800287D1 (cg-RX-API-DMAC10.html)
DK (2) DK0903345T3 (cg-RX-API-DMAC10.html)
ES (2) ES2166205T3 (cg-RX-API-DMAC10.html)
GR (1) GR3034814T3 (cg-RX-API-DMAC10.html)
HK (1) HK1049481B (cg-RX-API-DMAC10.html)
HU (2) HU225870B1 (cg-RX-API-DMAC10.html)
ID (1) ID20667A (cg-RX-API-DMAC10.html)
IL (1) IL125671A (cg-RX-API-DMAC10.html)
NO (1) NO310871B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ331270A (cg-RX-API-DMAC10.html)
PL (1) PL192126B1 (cg-RX-API-DMAC10.html)
PT (2) PT987256E (cg-RX-API-DMAC10.html)
RU (1) RU2224753C2 (cg-RX-API-DMAC10.html)
SK (2) SK282641B6 (cg-RX-API-DMAC10.html)
TR (2) TR200600582A1 (cg-RX-API-DMAC10.html)
TW (1) TW593288B (cg-RX-API-DMAC10.html)
UA (1) UA54411C2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US7022725B2 (en) * 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
LT2262790T (lt) * 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
GB9115377D0 (en) * 1991-07-17 1991-09-04 Rhone Poulenc Agriculture New compositions of matter
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (cg-RX-API-DMAC10.html) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Similar Documents

Publication Publication Date Title
JP2001521917A5 (cg-RX-API-DMAC10.html)
JP2003528100A5 (cg-RX-API-DMAC10.html)
JP2005526490A5 (cg-RX-API-DMAC10.html)
HUP0101230A2 (hu) Eljárás 2-[(2-piridil)-metilszulfinil]-1H-benzimidazol-származékok előállítására
SE7605819L (sv) Nya propargyl-2-fenylaminoimidazolin-(2), dess syraadditionssalter, lekemedel innehallande dessa och forfarande for framstellning derav
SE8201702L (sv) Forfarande for framstellning av en cefemforening i kristalliserad form
JP2004517948A5 (cg-RX-API-DMAC10.html)
NO126084B (cg-RX-API-DMAC10.html)
JP2002527374A5 (cg-RX-API-DMAC10.html)
JP2001181749A5 (cg-RX-API-DMAC10.html)
JP2000273225A5 (cg-RX-API-DMAC10.html)
DK421183D0 (da) Fremgangsmade til fremstilling af alfa-aryl-alfa-pyridylalkansyrer
JPS5217477A (en) Process for preparation of 1,2,3,4- tetrahydroisoquinolines and their salts
RU96109447A (ru) Способ получения порошка метастабильного кристаллического соединения bi2sio5
JPH06509084A (ja) 2−アミノナフチリジン誘導体の光学異性体の製造方法
SU570463A1 (ru) Способ удалени припо из отверстий
JPS5618947A (en) 2- 3-carbamoylphenyamino -n- 3,4-dimethoxyphenethyl acetamide trihydrate
UY24751A1 (es) Fabricacion del 7-bromo-5-(2-piridil)-3h-1,4-benzodiazepin-2h-ona.
JP2002520391A5 (cg-RX-API-DMAC10.html)
AT347953B (de) Verfahren zur herstellung von neuen derivaten des thiazolo (3,4-b) isochinolins und von ihren salzen
JPS57192376A (en) Purification of 2-mercaptothiazolines
JPS57158273A (en) Water ink
US221116A (en) Thaline nitrate
JPS5466625A (en) Purification of 2-bromo-3-methylbutyrylurea
TH65754A (th) กรรมวิธีสำหรับการทำสารประกอบให้บริสุทธิ์เชิงแสง